{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:17:11Z","timestamp":1791407831460,"version":"4.3.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T00:00:00Z","timestamp":1612742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T00:00:00Z","timestamp":1612742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["16770206"],"award-info":[{"award-number":["16770206"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K07625"],"award-info":[{"award-number":["19K07625"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s00262-021-02853-3","type":"journal-article","created":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T20:21:46Z","timestamp":1612902106000},"page":"2503-2515","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Enhanced anti-tumor efficacy of IL-7\/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models"],"prefix":"10.1007","volume":"70","author":[{"given":"Shunsuke","family":"Goto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukimi","family":"Sakoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keishi","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Sekido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Eto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3098-2565","authenticated-orcid":false,"given":"Koji","family":"Tamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,8]]},"reference":[{"issue":"5","key":"2853_CR1","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"SL Maude TW Laetsch J Buechner S Rives M Boyer H Bittencourt P Bader MR Verneris HE Stefanski GD Myers M Qayed B Moerloose De H Hiramatsu K Schlis KL Davis PL Martin ER Nemecek GA Yanik C Peters A Baruchel N Boissel F Mechinaud A Balduzzi J Krueger CH June BL Levine P Wood T Taran M Leung KT Mueller Y Zhang K Sen D Lebwohl MA Pulsipher SA Grupp 2018 Tisagenlecleucel in children and young adults with b-cell lymphoblastic leukemia N Engl J Med 378 5 439 448 https:\/\/doi.org\/10.1056\/NEJMoa1709866","journal-title":"N Engl J Med"},{"issue":"26","key":"2853_CR2","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"SS Neelapu FL Locke NL Bartlett LJ Lekakis DB Miklos CA Jacobson I Braunschweig OO Oluwole T Siddiqi Y Lin JM Timmerman PJ Stiff JW Friedberg IW Flinn A Goy BT Hill MR Smith A Deol U Farooq P McSweeney J Munoz I Avivi JE Castro JR Westin JC Chavez A Ghobadi KV Komanduri R Levy ED Jacobsen TE Witzig P Reagan A Bot J Rossi L Navale Y Jiang J Aycock M Elias D Chang J Wiezorek WY Go 2017 Axicabtagene ciloleucel car t-cell therapy in refractory large b-cell lymphoma N Engl J Med 377 26 2531 2544 https:\/\/doi.org\/10.1056\/NEJMoa1707447","journal-title":"N Engl J Med"},{"issue":"5","key":"2853_CR3","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"JH Park I Riviere M Gonen X Wang B Senechal KJ Curran C Sauter Y Wang B Santomasso E Mead M Roshal P Maslak M Davila RJ Brentjens M Sadelain 2018 Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia N Engl J Med 378 5 449 459 https:\/\/doi.org\/10.1056\/NEJMoa1709919","journal-title":"N Engl J Med"},{"issue":"1","key":"2853_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"SJ Schuster MR Bishop CS Tam EK Waller P Borchmann JP McGuirk U Jager S Jaglowski C Andreadis JR Westin I Fleury V Bachanova SR Foley PJ Ho S Mielke JM Magenau H Holte S Pantano LB Pacaud R Awasthi J Chu O Anak G Salles RT Maziarz 2019 Tisagenlecleucel in adult relapsed or refractory diffuse large b-cell lymphoma N Engl J Med 380 1 45 56 https:\/\/doi.org\/10.1056\/NEJMoa1804980","journal-title":"N Engl J Med"},{"issue":"6382","key":"2853_CR5","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"CH June RS O'Connor OU Kawalekar S Ghassemi MC Milone 2018 CAR T cell immunotherapy for human cancer Science 359 6382 1361 1365 https:\/\/doi.org\/10.1126\/science.aar6711","journal-title":"Science"},{"key":"2853_CR6","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1146\/annurev-immunol-042718-041407","volume":"37","author":"S Guedan","year":"2019","unstructured":"S Guedan M Ruella CH June 2019 Emerging cellular therapies for cancer Annu Rev Immunol 37 145 171 https:\/\/doi.org\/10.1146\/annurev-immunol-042718-041407","journal-title":"Annu Rev Immunol"},{"issue":"10","key":"2853_CR7","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"RG Majzner CL Mackall 2018 Tumor antigen escape from Car t-cell therapy Cancer Discov 8 10 1219 1226 https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0442","journal-title":"Cancer Discov"},{"key":"2853_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040842","author":"AJ Petty","year":"2020","unstructured":"AJ Petty B Heyman Y Yang 2020 Chimeric antigen receptor cell therapy: overcoming obstacles to battle cancer Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers12040842","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2853_CR9","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.coi.2013.02.009","volume":"25","author":"TF Gajewski","year":"2013","unstructured":"TF Gajewski SR Woo Y Zha R Spaapen Y Zheng L Corrales S Spranger 2013 Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment Curr Opin Immunol 25 2 268 276 https:\/\/doi.org\/10.1016\/j.coi.2013.02.009","journal-title":"Curr Opin Immunol"},{"key":"2853_CR10","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3389\/fimmu.2019.00128","volume":"10","author":"M Martinez","year":"2019","unstructured":"M Martinez EK Moon 2019 CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment Front Immunol 10 128 https:\/\/doi.org\/10.3389\/fimmu.2019.00128","journal-title":"Front Immunol"},{"issue":"3","key":"2853_CR11","doi-asserted-by":"publisher","first-page":"e994446","DOI":"10.4161\/2162402x.2014.994446","volume":"4","author":"M Koneru","year":"2015","unstructured":"M Koneru TJ Purdon D Spriggs S Koneru RJ Brentjens 2015 IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo Oncoimmunology 4 3 e994446 https:\/\/doi.org\/10.4161\/2162402x.2014.994446","journal-title":"Oncoimmunology"},{"issue":"11","key":"2853_CR12","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1158\/2159-8290.CD-17-0538","volume":"7","author":"T Shum","year":"2017","unstructured":"T Shum B Omer H Tashiro RL Kruse DL Wagner K Parikh Z Yi T Sauer D Liu R Parihar P Castillo H Liu MK Brenner LS Metelitsa S Gottschalk CM Rooney 2017 Constitutive signaling from an engineered IL7 receptor promotes durable tumor elimination by tumor-redirected T cells Cancer Discov 7 11 1238 1247 https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0538","journal-title":"Cancer Discov"},{"issue":"10","key":"2853_CR13","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1111\/cas.14169","volume":"110","author":"M Nakajima","year":"2019","unstructured":"M Nakajima Y Sakoda K Adachi H Nagano K Tamada 2019 Improved survival of chimeric antigen receptor-engineered T (CAR-T) and tumor-specific T cells caused by anti-programmed cell death protein 1 single-chain variable fragment-producing CAR-T cells Cancer Sci 110 10 3079 3088 https:\/\/doi.org\/10.1111\/cas.14169","journal-title":"Cancer Sci"},{"issue":"3","key":"2853_CR14","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00262-018-2281-2","volume":"68","author":"W Hu","year":"2019","unstructured":"W Hu Z Zi Y Jin G Li K Shao Q Cai X Ma F Wei 2019 CRISPR\/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions Cancer Immunol Immunother 68 3 365 377 https:\/\/doi.org\/10.1007\/s00262-018-2281-2","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"2853_CR15","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","volume":"26","author":"CC Kloss","year":"2018","unstructured":"CC Kloss J Lee A Zhang F Chen JJ Melenhorst SF Lacey MV Maus JA Fraietta Y Zhao CH June 2018 Dominant-negative TGF-beta receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication Mol Ther 26 7 1855 1866 https:\/\/doi.org\/10.1016\/j.ymthe.2018.05.003","journal-title":"Mol Ther"},{"key":"2853_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4478","author":"Y Kagoya","year":"2018","unstructured":"Y Kagoya S Tanaka T Guo M Anczurowski CH Wang K Saso MO Butler MD Minden N Hirano 2018 A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects Nat Med https:\/\/doi.org\/10.1038\/nm.4478","journal-title":"Nat Med"},{"key":"2853_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4086","author":"K Adachi","year":"2018","unstructured":"K Adachi Y Kano T Nagai N Okuyama Y Sakoda K Tamada 2018 IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor Nat Biotechnol https:\/\/doi.org\/10.1038\/nbt.4086","journal-title":"Nat Biotechnol"},{"issue":"1","key":"2853_CR18","doi-asserted-by":"publisher","first-page":"424","DOI":"10.4049\/jimmunol.169.1.424","volume":"169","author":"SA Luther","year":"2002","unstructured":"SA Luther A Bidgol DC Hargreaves A Schmidt Y Xu J Paniyadi M Matloubian JG Cyster 2002 Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis J Immunol 169 1 424 433","journal-title":"J Immunol"},{"issue":"11","key":"2853_CR19","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1038\/ni1513","volume":"8","author":"A Link","year":"2007","unstructured":"A Link TK Vogt S Favre MR Britschgi H Acha-Orbea B Hinz JG Cyster SA Luther 2007 Fibroblastic reticular cells in lymph nodes regulate the homeostasis of naive T cells Nat Immunol 8 11 1255 1265 https:\/\/doi.org\/10.1038\/ni1513","journal-title":"Nat Immunol"},{"issue":"2","key":"2853_CR20","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.canlet.2007.04.012","volume":"255","author":"L Bergan","year":"2007","unstructured":"L Bergan JA Gross B Nevin N Urban N Scholler 2007 Development and in vitro validation of anti-mesothelin biobodies that prevent CA125\/Mesothelin-dependent cell attachment Cancer Lett 255 2 263 274 https:\/\/doi.org\/10.1016\/j.canlet.2007.04.012","journal-title":"Cancer Lett"},{"issue":"3","key":"2853_CR21","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/mt.2011.256","volume":"20","author":"E Lanitis","year":"2012","unstructured":"E Lanitis M Poussin IS Hagemann G Coukos R Sandaltzopoulos N Scholler DJ Powell Jr 2012 Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor Mol Ther 20 3 633 643 https:\/\/doi.org\/10.1038\/mt.2011.256","journal-title":"Mol Ther"},{"issue":"4","key":"2853_CR22","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","volume":"18","author":"RA Morgan","year":"2010","unstructured":"RA Morgan JC Yang M Kitano ME Dudley CM Laurencot SA Rosenberg 2010 Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2 Mol Ther 18 4 843 851 https:\/\/doi.org\/10.1038\/mt.2010.24","journal-title":"Mol Ther"},{"issue":"23","key":"2853_CR23","doi-asserted-by":"publisher","first-page":"6436","DOI":"10.1158\/1078-0432.CCR-12-1449","volume":"18","author":"K Tamada","year":"2012","unstructured":"K Tamada D Geng Y Sakoda N Bansal R Srivastava Z Li E Davila 2012 Redirecting gene-modified T cells toward various cancer types using tagged antibodies Clin Cancer Res: Off J Am Assoc Cancer Res 18 23 6436 6445 https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-1449","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"key":"2853_CR24","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.csbj.2016.09.003","volume":"14","author":"M Ruella","year":"2016","unstructured":"M Ruella MV Maus 2016 Catch me if you can: leukemia escape after CD19-directed T Cell immunotherapies Comput Struct Biotechnol J 14 357 362 https:\/\/doi.org\/10.1016\/j.csbj.2016.09.003","journal-title":"Comput Struct Biotechnol J"},{"key":"2853_CR25","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.3389\/fimmu.2020.01109","volume":"11","author":"A Rodriguez-Garcia","year":"2020","unstructured":"A Rodriguez-Garcia A Palazon E Noguera-Ortega DJ Powell Jr S Guedan 2020 CAR-T cells hit the tumor microenvironment: strategies to overcome tumor escape Front Immunol 11 1109 https:\/\/doi.org\/10.3389\/fimmu.2020.01109","journal-title":"Front Immunol"},{"key":"2853_CR26","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.3389\/fonc.2019.01237","volume":"9","author":"J Cheng","year":"2019","unstructured":"J Cheng L Zhao Y Zhang Y Qin Y Guan T Zhang C Liu J Zhou 2019 Understanding the mechanisms of resistance to CAR T-Cell therapy in malignancies Front Oncol 9 1237 https:\/\/doi.org\/10.3389\/fonc.2019.01237","journal-title":"Front Oncol"},{"issue":"18","key":"2853_CR27","doi-asserted-by":"publisher","first-page":"4062","DOI":"10.1158\/1078-0432.Ccr-15-0428","volume":"21","author":"CE Brown","year":"2015","unstructured":"CE Brown B Badie ME Barish L Weng JR Ostberg WC Chang A Naranjo R Starr J Wagner C Wright Y Zhai JR Bading JA Ressler J Portnow M D'Apuzzo SJ Forman MC Jensen 2015 Bioactivity and safety of IL13Ralpha2-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma Clin Cancer Res: Off J Am Assoc Cancer Res 21 18 4062 4072 https:\/\/doi.org\/10.1158\/1078-0432.Ccr-15-0428","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"key":"2853_CR28","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa0984","author":"DM Orourke","year":"2017","unstructured":"DM Orourke MP Nasrallah A Desai JJ Melenhorst K Mansfield JJD Morrissette M Martinezlage S Brem E Maloney A Shen R Isaacs S Mohan G Plesa SF Lacey JM Navenot Z Zheng BL Levine H Okada CH June JL Brogdon MV Maus 2017 A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma Sci Transl Med https:\/\/doi.org\/10.1126\/scitranslmed.aaa0984","journal-title":"Sci Transl Med"},{"issue":"1","key":"2853_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4143\/crt.2017.307","volume":"50","author":"J Jung","year":"2018","unstructured":"J Jung HS Seol S Chang 2018 The generation and application of patient-derived xenograft model for cancer research Cancer Res Treat 50 1 1 10 https:\/\/doi.org\/10.4143\/crt.2017.307","journal-title":"Cancer Res Treat"},{"issue":"2","key":"2853_CR30","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1158\/0008-5472.CAN-16-1911","volume":"78","author":"TT Byrd","year":"2018","unstructured":"TT Byrd K Fousek A Pignata C Szot H Samaha S Seaman L Dobrolecki VS Salsman HZ Oo K Bielamowicz D Landi N Rainusso J Hicks S Powell ML Baker WS Wels J Koch PH Sorensen B Deneen MJ Ellis MT Lewis M Hegde BS Fletcher B St Croix N Ahmed 2018 TEM8\/ANTXR1-specific CAR T cells as a targeted therapy for triple-negative breast cancer Cancer Res 78 2 489 500 https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-1911","journal-title":"Cancer Res"},{"issue":"1","key":"2853_CR31","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ymthe.2019.10.010","volume":"28","author":"C Deng","year":"2020","unstructured":"C Deng J Zhao S Zhou J Dong J Cao J Gao Y Bai H Deng 2020 The vascular disrupting agent CA4P improves the antitumor efficacy of CAR-T cells in preclinical models of solid human tumors Mol Ther 28 1 75 88 https:\/\/doi.org\/10.1016\/j.ymthe.2019.10.010","journal-title":"Mol Ther"},{"key":"2853_CR32","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.omto.2020.04.008","volume":"17","author":"Z Hu","year":"2020","unstructured":"Z Hu X Zheng D Jiao Y Zhou R Sun B Wang Z Tian H Wei 2020 LunX-CAR T cells as a targeted therapy for non-small cell lung cancer Mol Ther Oncolytics 17 361 370 https:\/\/doi.org\/10.1016\/j.omto.2020.04.008","journal-title":"Mol Ther Oncolytics"},{"issue":"12","key":"2853_CR33","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1007\/s13238-017-0472-9","volume":"8","author":"H Jiang","year":"2017","unstructured":"H Jiang B Song P Wang B Shi Q Li M Fan S Di J Yang Z Li 2017 Efficient growth suppression in pancreatic cancer PDX model by fully human anti-mesothelin CAR-T cells Prot Cell 8 12 926 931 https:\/\/doi.org\/10.1007\/s13238-017-0472-9","journal-title":"Prot Cell"},{"key":"2853_CR34","doi-asserted-by":"publisher","first-page":"690","DOI":"10.3389\/fimmu.2016.00690","volume":"7","author":"Z Jiang","year":"2016","unstructured":"Z Jiang X Jiang S Chen Y Lai X Wei B Li S Lin S Wang Q Wu Q Liang Q Liu M Peng F Yu J Weng X Du D Pei P Liu Y Yao P Xue P Li 2016 Anti-GPC3-CAR T cells suppress the growth of tumor cells in patient-derived xenografts of hepatocellular carcinoma Front Immunol 7 690 https:\/\/doi.org\/10.3389\/fimmu.2016.00690","journal-title":"Front Immunol"},{"key":"2853_CR35","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133977","author":"N Tang","year":"2020","unstructured":"N Tang C Cheng X Zhang M Qiao N Li W Mu XF Wei W Han H Wang 2020 TGF-beta inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.133977","journal-title":"JCI Insight"},{"issue":"3","key":"2853_CR36","doi-asserted-by":"publisher","first-page":"e1284722","DOI":"10.1080\/2162402X.2017.1284722","volume":"6","author":"X Wei","year":"2017","unstructured":"X Wei Y Lai J Li L Qin Y Xu R Zhao B Li S Lin S Wang Q Wu Q Liang M Peng F Yu Y Li X Zhang Y Wu P Liu D Pei Y Yao P Li 2017 PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells Oncoimmunology 6 3 e1284722 https:\/\/doi.org\/10.1080\/2162402X.2017.1284722","journal-title":"Oncoimmunology"},{"issue":"1","key":"2853_CR37","doi-asserted-by":"publisher","first-page":"e1509173","DOI":"10.1080\/2162402X.2018.1509173","volume":"8","author":"R Zhao","year":"2019","unstructured":"R Zhao L Cheng Z Jiang X Wei B Li Q Wu S Wang S Lin Y Long X Zhang Y Wu X Du D Pei P Liu Y Li S Cui Y Yao P Li 2019 DNAX-activating protein 10 co-stimulation enhances the anti-tumor efficacy of chimeric antigen receptor T cells Oncoimmunology 8 1 e1509173 https:\/\/doi.org\/10.1080\/2162402X.2018.1509173","journal-title":"Oncoimmunology"},{"key":"2853_CR38","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1146\/annurev-pathol-052016-100332","volume":"12","author":"NC Walsh","year":"2017","unstructured":"NC Walsh LL Kenney S Jangalwe KE Aryee DL Greiner MA Brehm LD Shultz 2017 Humanized mouse models of clinical disease Annu Rev Pathol 12 187 215 https:\/\/doi.org\/10.1146\/annurev-pathol-052016-100332","journal-title":"Annu Rev Pathol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-021-02853-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-021-02853-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-021-02853-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T12:06:35Z","timestamp":1628769995000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-021-02853-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,8]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["2853"],"URL":"https:\/\/doi.org\/10.1007\/s00262-021-02853-3","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,8]]},"assertion":[{"value":"25 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"K.T. and Yu.S. hold stocks of Noile-Immune Biotech Inc., and receive remuneration from Noile-Immune Biotech Inc. Other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All animal procedures were approved by the Institutional Animal Care and Use Committee of the Yamaguchi University. Human PBMCs were derived from healthy volunteers who gave a written informed consent. Patient-derived xenograft tumor was derived from a pancreatic cancer patient who gave written informed consent. This study was approved by the ethics committee of the Yamaguchi University.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}